期刊文献+

Roche电化学发光免疫法检测NT—proBNP的检测限值和功能灵敏度研究 被引量:2

Research on Limits of Detection and Sensitivity of Roche Electrochemiluminescence Immunoassay in the Detection of NT-proBNP
下载PDF
导出
摘要 目的探讨电化学发光免疫法检测N末端B型利钠肽原(NT—proBNP)的检测限值和功能灵敏度。方法参照美国临床和实验室标准化协会(CLSI)Ep-17A文件制备空白样品及系列低浓度样品。‘空白样品采用配套的稀释液,系列低浓度样品采用倍比稀释的方法获得。样品制备后用RocheCobasE601电化学发光免疫系统检测NT-proBNP浓度,以确定该方法的空白限、检出限和功能灵敏度。结果NT—proBNP的空白限为2.53pg/ml,检出限为7.75pg/ml,10%CV时的功能灵敏度为8.82pg/ml。结论建立了RocheCobasE601电化学发光免疫系统检测NT-proBNP的空白限、检出限和功能灵敏度,为临床诊断和治疗提供了更有价值的信息。 Objective To evaluate the limits of detection and functional sensitivity of electro-chemiluminescence immunoassay in detection of NT-proBNP using Clinical and Laboratory Standards Institute(CLSI)EP-17A. Methods Blank and a serial low consistency samples were detected by Roche Cobas E601 electrochemiluminescence immunoassay system to establish the limit of blank,limit of detection and functional sensitivity of NT-proBNP. Suporting diluent was blank sample and a serial low consistency samples were abtained by dilution. Results The limit of blank and limit of detection of NT-proBNP was 2.53 pg/ml,7.75 pg/ml,respectively. The functional sensitivity was 8. 82 pg/ml. Conclusion The limit of blank,limit of detection and functional sensitivity were established successfully in laboratories, which could provide more important infor- mation for the clinical diagnosis and therapy.
出处 《现代检验医学杂志》 CAS 2012年第1期104-106,109,共4页 Journal of Modern Laboratory Medicine
基金 基金项目:广东省医学科研基金课题(A2009763),中山市科技局资助课题(20091A038).
关键词 N末端B型利钠肽原 电化学发光免疫法 空白限 检出限 功能灵敏度 N-terminal pro-brain natriuretic peptide limit of blank limit of detection electrochemiluminescence Immunoassay functional sensitivity
  • 相关文献

参考文献9

  • 1Murray H,Cload B,Collier CP,et al. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea [J]. CJEM, 2006,8(4) : 251-258.
  • 2Clerico A, Fontana M, Zyw L, et al. Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Fail- ure: A Systematic Review [J] . Clin Chem, 2007, 53 (5) :813-822.
  • 3Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult[J]. Circula- tion,2005,112(12) :e154-e235.
  • 4CLSI EP-17A. Protocols for Determination of Limits of Detection and Limits of Quantitation. Approved Guideline[S]. CLSI EP-17A,Wayne PA: 2004,1-39.
  • 5Tang WH, Francis GS, Morrow DA, et, al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure[J]. Clin Biochem, 2008,41(4/5) :210-221.
  • 6Rawlins ML, Owen WE, Roberts WI Performance Characteristics of Four Automated Natriuretic Pep- tide Assays[J]. Am J Clin Pathol, 2005,123 (3) : 439-445.
  • 7Prontera C, Emdin M, Zucchelli GC, et. al. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide[J]. Clin Chem Lab Med, 2004,42 (1) : 37-44.
  • 8Yeo KT,Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay[J]. Clinica Chimica Acta. 2003. 338(1/2) : 107-115.
  • 9杨有业,张秀明.临床检验方法学评价[M].北京:人民卫生出版社,2008:118-127.

共引文献172

同被引文献23

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部